Table I.
Baseline demographic data of older HL patients.
| Treatment Arms | ||||
|---|---|---|---|---|
| ABVD (n=23) | Stanford V (n=21) | |||
| N | % | N | % | |
| Age (years) | 66 | 64 | ||
| Median | ||||
| Range | 61–83 | 60–83 | ||
| Gender | ||||
| Male | 11 | 49 | 13 | 63 |
| Female | 12 | 52 | 8 | 38 |
| ECOG PS | 6 | 26 | 9 | 43 |
| 0 | ||||
| 1 | 16 | 70 | 12 | 57 |
| 2 | 1 | 4 | . | . |
| B symptoms | 12 | 52 | 11 | 52 |
| No | ||||
| Yes | 11 | 48 | 10 | 48 |
| Disease Stage | 1 | 4 | 2 | 9 |
| II | ||||
| III | 17 | 74 | 13 | 62 |
| IV | 5 | 22 | 6 | 29 |
| Cell type | 2 | 9 | . | . |
| NA | ||||
| Nodular sclerosis | 11 | 48 | 11 | 52 |
| Lymphocyte-rich | . | . | 1 | 5 |
| Mixed cellularity | 7 | 30 | 4 | 19 |
| Classical HL, NOS | 3 | 13 | 5 | 24 |
| No. extra-nodal sites | 18 | 78 | 15 | 71 |
| 0 | ||||
| 1 | 3 | 13 | 4 | 19 |
| 2 | 2 | 9 | . | . |
| 4 | . | . | 1 | 5 |
| 5 | . | . | 1 | 5 |
| Lung involvement | 21 | 91 | 18 | 86 |
| No | ||||
| Yes | 2 | 9 | 3 | 14 |
| Liver involvement | 21 | 91 | 19 | 91 |
| No | ||||
| Yes | 2 | 9 | 2 | 9 |
| Bone marrow involvement | 22 | 96 | 19 | 91 |
| No | ||||
| Yes | 1 | 4 | 2 | 9 |
| Mediastinal involvement | 10 | 44 | 4 | 19 |
| No | ||||
| Yes | 13 | 56 | 17 | 81 |
| IPS risk factors | . | . | 1 | 5 |
| NA | ||||
| 1 | 4 | 17 | 2 | 9 |
| 2 | 10 | 44 | 10 | 48 |
| 3 | 7 | 30 | 2 | 9 |
| 4 | 2 | 9 | 1 | 5 |
| 5 | . | . | 4 | 19 |
| 6 | . | . | 1 | 5 |
Abbreviations: HL, Hodgkin lymphoma; NA, not available; ECOG, Eastern Cooperative Oncology Group; PS, performance status; NOS, not otherwise specified; IPS, International Prognostic Score; ABVD, adriamycin, bleomycin, vinblastine, dacarbazine.